GreenMark Biomedical Healthcare Innovation Spotlight: The Corn-Derived Nanoparticle Technology Remineralizing Teeth From the Inside Out
Introduction: When a Corn Field Holds the Answer to the World’s Most Common Disease
Dental caries, more commonly known as tooth decay, affects an estimated 3.7 billion people worldwide and touches more than 95% of Americans over the course of their lifetimes. It is the most prevalent chronic disease on the planet. Yet for decades, the standard treatment has barely changed: drill, fill, and, when things get bad enough, crown. That approach treats the damage after it has already happened.
A Michigan-based biomedical company is proposing something different. Using food-grade corn starch nanoparticles, GreenMark Biomedical is working to remineralize teeth from the inside out, targeting the sub-surface porosities where decay actually begins rather than simply patching the surface.
The full story of that innovation appears in TopDoctor Magazine Issue 195, which delivers something the flurry of press releases and trade briefs never managed: a comprehensive, long-form narrative connecting the science, the founding mission, the leadership team, and the milestone cascade that has defined the company’s recent trajectory. This GreenMark Biomedical healthcare innovation spotlight explores that founding vision, the corn-derived technology, the peer-reviewed validation, the NIH grant momentum, and what it all means for the future of dentistry.
The Problem Worth Solving: Dental Caries as a Global Chronic Disease Crisis
According to the CDC and the World Health Organization, oral diseases affect roughly 3.7 billion people, with dental caries accounting for most cases. That scale makes tooth decay a genuine global health crisis, not a minor inconvenience.
The traditional treatment paradigm is fundamentally reactive. Drilling, filling, and crowning address the consequences of decay after enamel has been irreversibly compromised. They do little to interrupt the underlying disease process at its earliest, most treatable stage.
The economic dimension is staggering. The global dental services market was valued between approximately $440 billion and $499 billion in 2025 and is projected to reach anywhere from $795 billion to $1.15 trillion by 2034 and 2035, with minimally invasive and preventive care identified as key growth drivers.
The biological opportunity sits in early-stage caries, when enamel develops sub-surface porosity before a true cavity forms. This is a window during which noninvasive intervention is still possible. The obvious question follows: why has a disease this common, this costly, and this treatable at early stages not been addressed by a targeted, science-backed, noninvasive solution until now?
GreenMark Biomedical: A Company Built on a Founding Mission
GreenMark Biomedical Inc. is a Michigan-based minimally invasive healthcare company founded in 2016. Its mission, stated in the company’s own words, is “to enable oral healthcare professionals to preserve teeth through earlier diagnosis and noninvasive treatment.”
That founding vision did not appear in a vacuum. It emerged from decades of biomaterials research and hard-won entrepreneurial experience. By launching in 2016, GreenMark positioned itself ahead of the broader shift in dentistry toward the medical management of caries, arriving before the clinical and regulatory moment had fully caught up.
Central to the effort is a collaboration with the University of Michigan. The company’s technology was co-invented alongside university researchers, including Dr. Joerg Lahann in biomaterials and Dr. Brian Clarkson by cariology, with the university holding licenses on key research. That institutional partnership gave GreenMark a foundation rooted in rigorous academic science.
Meet the Founder: Dr. Steven Bloembergen’s Journey from Cleantech IPO to Dental Innovation
At the intellectual and entrepreneurial center of GreenMark stands Dr. Steven Bloembergen, the company’s Chairman and CEO. He is the inventor of more than 25 patent families related to biomaterials, making him one of the most prolific researchers in the starch nanoparticle space.
His track record extends well beyond the laboratory. Bloembergen co-founded EcoSynthetix Inc. (TSX: ECO), which held Canada’s largest Cleantech IPO in August 2011 and built starch nanoparticle manufacturing capacity exceeding 200 million pounds per year. That history matters: the science underpinning GreenMark is not theoretical but commercially proven at industrial scale.
In 2025, Bloembergen received the Shils Entrepreneurial Fund “Excellence in Research” Award at the NYU College of Dentistry, recognizing his groundbreaking advancements in tooth remineralization and caries prevention.
GreenMark is not a pivot or a coincidence. It is the deliberate application of decades of materials science expertise to an unmet dental health need. Bloembergen’s mastery of starch nanoparticle manufacturing informs the company’s technology platform directly.
The Leadership Team Profiled in TopDoctor Issue 195
TopDoctor Magazine Issue 195 features three leaders on its cover: a complementary team whose combined expertise spans science, technology, and clinical affairs. Together they represent the full arc required to move an idea from the bench to the dental chair.
Dr. Nathan Jones, VP of Technology
Dr. Nathan Jones leads the translation of starch nanoparticle science into engineered product platforms. He has contributed to the development of both CrystLCare™ and LumiCare™ as distinct yet integrated product lines.
That work embodies the technology translation challenge. Moving from academic lab results at the University of Michigan to scalable, FDA-clearable medical devices requires a specific kind of applied engineering leadership: the ability to preserve scientific integrity while designing for manufacturability and regulatory approval.
Dr. Wendy Bloembergen, VP of Clinical Affairs
Dr. Wendy Bloembergen bridges the science with clinical practice, ensuring GreenMark’s products are designed around real-world dental workflows and patient needs.
Her role is critical to the regulatory pathway. Clinical affairs leadership underpins FDA 510(k) submissions and future clearance applications for CrystLCare™. Her clinical perspective also shapes the company’s patient-centered mission, connecting laboratory innovation to the actual chair-side experience.
The Science Explained: How Corn Starch Nanoparticles Remineralize Teeth From the Inside Out
At its foundation, GreenMark’s technology platform is built on bioresorbable starch nanoparticles derived from American-grown corn, using food-grade starch.
The key biological mechanism is elegant. These nanoparticles are degraded by natural enzymes already present in human saliva, making them a safe, body-compatible carrier for dental applications. No synthetic chemicals or foreign materials are left behind.
This contrasts sharply with conventional fluoride treatments. Fluoride works only at the enamel surface. CrystLCare™ enables mineral ions to penetrate into sub-surface enamel porosities, precisely where early decay actually begins.
The nanoparticles deliver calcium and phosphate ions that form hydroxyapatite crystals, the same mineral that makes up natural tooth enamel. These crystals occlude exposed dentinal tubules and rebuild enamel from within.
This approach is not merely a company claim. GreenMark’s research was published in JADA Foundational Science in December 2024, the peer-reviewed journal of the American Dental Association, under the title “Targeted Enamel Remineralization with Mineral-Loaded Starch Particles.” Micro-computed tomography findings from testing showed that CrystLCare™ outperformed fluoride, demonstrating superior sub-surface enamel mineral regeneration, a result that distinguishes GreenMark’s approach from every existing remineralization product on the market.
CrystLCare™ Biorestorative: The Dissolvable Strip Rewriting the Rules of Cavity Prevention
CrystLCare™ Biorestorative (Fluoride-Free) is GreenMark’s flagship treatment product: a dissolvable dental strip that delivers calcium and phosphate ions via starch microparticles.
The patient experience is straightforward. The strip dissolves naturally in the mouth, releasing mineral-loaded nanoparticles that saliva enzymes guide to the sites of early enamel demineralization.
The fluoride-free formulation is a significant market differentiator, addressing growing consumer demand for fluoride-free oral care options without sacrificing efficacy. That combination, natural-leaning yet clinically validated, is rare in the oral care market.
GreenMark’s regulatory roadmap extends further. The company is pursuing FDA clearance for fluoride-containing versions of CrystLCare™ and for the specific indication of treating early-stage dental caries, a pathway that would position the product as a prescription-grade therapeutic rather than merely a preventive aid. CrystLCare™ anchors the “treat” pillar of GreenMark’s integrated three-pillar vision: detect, prevent, and treat.
LumiCare™ and LumiVision™: Seeing Decay Before It Becomes a Cavity
LumiCare™ Caries Detection Rinse is GreenMark’s FDA 510(k) Class II Medical Device-cleared diagnostic product, marking the company’s first regulatory milestone.
The mechanism relies on fluorescent starch nanoparticles in the rinse that illuminate sub-surface porosities in enamel under specific light conditions, enabling dentists to detect early caries invisible to conventional examination.
The clinical significance is direct: earlier detection means earlier intervention. It identifies the precise window during which noninvasive remineralization with CrystLCare™ remains possible, before irreversible structural damage demands drilling.
LumiVision™ represents the next-generation evolution: an AI-enabled intraoral camera currently in development under a Phase I SBIR grant from the NIH/NIDCR. It is designed to integrate fluorescent caries detection directly into the dental imaging workflow. Together, LumiCare™ and LumiVision™ form the “detect” pillar of GreenMark’s ecosystem, the diagnostic front end that makes the treatment back end clinically actionable.
NIH Grant Momentum: Why Federal Science Funders Are Betting on GreenMark
NIH and NIDCR grant awards represent one of the most credible external validations a biomedical startup can earn. They are competitive, peer-reviewed, and independent of commercial interests.
In 2025, GreenMark secured a grant trifecta: a Phase I SBIR grant for AI-enabled LumiVision™ intraoral camera development; a $300,000 SBIR grant for noninvasive mineralization of early-stage dental caries in collaboration with the University of Michigan; and additional Translational Resource Center (TRC) funding.
The momentum continued into August 2026, when GreenMark secured a follow-on TRC grant of up to $297,615 to advance new forms of its regenerative products for noninvasive mineralization of early-stage dental decay, the most recent milestone confirming continued federal confidence in the platform.
TRC funding is specifically designed to bridge the gap between academic research and commercial product development, accelerating the path from lab to market. Taken together, multiple independent awards across different product lines signal that GreenMark’s science is reproducible, its team is credible, and its commercial opportunity is recognized at the highest levels of U.S. biomedical research funding.
JADA Publication and the Shils Award: Peer-Reviewed Credibility Meets Entrepreneurial Recognition
Publication in JADA Foundational Science in December 2024 carries substantial weight. As the peer-reviewed journal of the American Dental Association, JADA represents the gold standard of scientific credibility for the dental profession.
The key findings of “Targeted Enamel Remineralization with Mineral-Loaded Starch Particles” confirmed sub-surface remineralization via mineral-loaded starch particles, verified by micro-computed tomography, outperforming fluoride in the critical sub-surface zone.
This matters for adoption. Clinicians are trained to follow evidence-based practice, and a JADA-published study provides the clinical justification for incorporating GreenMark’s products into patient care protocols.
Recognition extended beyond the journal page. The 2025 Shils Entrepreneurial Fund “Excellence in Research” Award at the NYU College of Dentistry validated both the science and the entrepreneurial execution. Earlier, GreenMark won the “Best Startup” award at the 2023 Yankee Dental Meeting’s Startup Central Pitch event, organized by Revere Partners, with eligibility for a $50,000 investment award.
Why TopDoctor Magazine Issue 195 Tells the Story No One Else Has
Dental trade publications such as Dental Products Report, Oral Health Group, and Dentistry33 have covered GreenMark’s FDA clearance and NIH grants, largely in press-release format. None produced a comprehensive narrative profile.
TopDoctor Issue 195 provides something different: the full GreenMark story. It connects Dr. Bloembergen’s EcoSynthetix entrepreneurial history, the University of Michigan collaboration, the food-grade corn starch science, the leadership team’s complementary expertise, and the 2025 and 2026 milestone trajectory into a single authoritative narrative.
The white space is notable. No major general healthcare media outlet has yet profiled GreenMark Biomedical, making Issue 195 the definitive general-audience reference for this story.
TopDoctor Magazine’s editorial approach combines human-interest profiles with scientific credibility, bridging the gap between peer-reviewed JADA data and the patient or practitioner who needs it explained in plain language. The GreenMark Biomedical healthcare innovation spotlight in Issue 195 represents exactly the kind of exclusive, depth-first coverage the magazine’s editorial mission was built to deliver.
The Bigger Picture: What GreenMark’s Success Means for the Future of Dentistry
GreenMark represents a genuine paradigm shift: a move from reactive, surgical dentistry toward the medical management of caries as a chronic disease. The analogy to cardiology is apt, where the profession shifted from treating heart attacks to preventing them.
The implications for practice are profound. If LumiCare™ and LumiVision™ enable earlier detection and CrystLCare™ enables noninvasive treatment of early lesions, the entire clinical workflow of a dental practice could evolve, with consequences for patient outcomes, practice economics, and insurance reimbursement models.
For health-conscious consumers, the fluoride-free, food-grade, corn-derived technology offers a natural-leaning yet scientifically validated alternative to conventional fluoride treatments, a rare combination in the oral care market. Patients interested in broader health trends doctors are watching in 2026 will find GreenMark’s noninvasive approach emblematic of the preventive medicine movement reshaping multiple specialties.
The addressable market is enormous. With 3.7 billion people affected by dental caries and a dental services market projected to exceed $1 trillion by 2034, GreenMark’s commercial runway is substantial if clinical adoption follows scientific validation. Woven through it all is an American innovation story: American-grown corn, University of Michigan research, NIH federal funding, and Michigan-based entrepreneurship converging to address one of humanity’s oldest health problems.
Conclusion: From the Cornfield to the Dental Chair
The narrative arc is coherent and compelling. Dr. Steven Bloembergen’s decades of starch nanoparticle expertise, the 2016 founding mission, the University of Michigan collaboration, and the 2025 and 2026 milestone cascade (including JADA publication, three NIH grants, the Shils Award, and the August 2026 TRC follow-on) together tell the story of science-driven healthcare innovation reaching a commercial inflection point.
For general readers, the central insight is striking: the answer to one of the world’s most common diseases may have been growing in American cornfields all along, and GreenMark Biomedical is the company translating that insight into clinical reality.
TopDoctor Magazine Issue 195 makes this story accessible, combining the credibility of peer-reviewed research with the depth of a leadership profile. As GreenMark advances toward additional FDA clearances, expands its NIH-funded research, and moves CrystLCare™ and LumiVision™ closer to broad adoption, this healthcare innovation spotlight will only grow more relevant. Connecting innovators, practitioners, and patients through stories that matter is precisely TopDoctor Magazine’s editorial mission, and GreenMark is exactly the kind of story that matters.
Explore the Full GreenMark Biomedical Feature in TopDoctor Magazine Issue 195
Readers seeking the complete cover feature on GreenMark Biomedical, including the full leadership profiles of Dr. Steven Bloembergen, Dr. Nathan Jones, and Dr. Wendy Bloembergen, will find it in TopDoctor Magazine Issue 195.
To stay current on healthcare innovations like GreenMark’s corn-derived nanoparticle technology, readers can subscribe to TopDoctor Magazine’s free biweekly newsletter.
Dental professionals are encouraged to explore how TopDoctor Magazine connects medical companies with practitioners, and how GreenMark Biomedical’s detect-prevent-treat platform may be relevant to their practice. Practitioners looking to connect with peers around emerging technologies may also find value in healthcare networking events for doctors in 2026 as the field continues to evolve.
To learn more about CrystLCare™, LumiCare™, and the company’s ongoing research programs, readers can visit GreenMark Biomedical’s official website at greenmark.bio.
